With the impending legalization of marijuana in Canada, what do plan sponsors need to consider? How will the workplace be affected by both recreational and medical marijuana? What are the legal implications? Should benefits plans cover medical marijuana? All these topics and more will be on the table during a panel discussion at Benefits Canada’s 2018 […]
The hepatitis C hump is over. Since 2014, Health Canada has approved several promising medications for the disease. While the direct-acting antivirals offer cure rates of more than 90 per cent, they cost tens of thousands of dollars, and benefits plans felt the pinch. But now, “after an initial spike in treatment requests, claims have […]
British Columbia is expanding treatment coverage for chronic hepatitis C to everyone in the province and has added a new drug to the province’s PharmaCare formulary. “In years past, a hepatitis C diagnosis was a stressful and lifelong struggle,” said Health Minister Adrian Dix, in a news release. “I’m pleased to share that, as of today, anyone […]
Green Shield Canada is rolling out a new biosimilar transition program as a pilot project through the first half of 2018, with an aim to extending it to all of its employer clients by the end of the year. The program, which was designed to help plan members transition from an originator drug to a corresponding biosimilar, will initially focus […]
A group of 28 patient advocacy organizations are urging Health Canada to stop its review of drug pricing. The federal government announced changes to drug price regulation in December 2017, setting out proposals through the Patented Medicine Prices Review Board that it estimates will deliver $12.6 billion in net benefits over 10 years through lower drug costs. Read: Feds […]
Counterfeit pharmaceutical drugs are a rising risk to Canadians as they’re appearing in brick-and-mortar pharmacies, rather than just on the street or online, according to a new report by public policy think tank the Fraser Institute. It’s also a growing issue internationally and one that’s attracting the attention of policy-makers. But what does it mean for group benefits plans? Counterfeit […]
Almost one million Canadians cut spending on necessities such as food and heating to afford prescription drugs in 2016, according to a report by researchers at the University of British Columbia, Simon Fraser University, McMaster University and the University of Toronto. The report, which used data from Statistics Canada’s 2016 Canadian community health survey, also found 1.69 […]
British Columbia’s plan to eliminate or reduce prescription drug deductibles for low-income earners could also lead to lower drug costs for plan sponsors in the province. While Nick Gubbay, a principal and group benefits consultant at Eckler Ltd. in Vancouver, says the impact is likely to be most material for group plans providing benefits to […]
As the new year gets underway, it’s a busy season for predictions about what’s ahead for 2018. When it comes to employer-sponsored drug plans, costs have been a rising concern in recent years. According to projections released by Aon Hewitt in December, costs for extended health-care plans will likely rise by six per cent in […]
Canadians continue to pay more than most other Organisation for Economic Co-operation and Development countries for generic drugs, despite provincial and territorial policies that have greatly reduced prices in recent years, according to a new report by the Patented Medicine Prices Review Board. The Generics360 report found Canadians spent $165 per capita on generic drugs […]